Our results indicated that expression of TRIM22, IFI6, IFITM1, IFI35, and IRF9 was related to disease diagnosis and that these genes could act as biomarkers to verify the diagnosis of PM/DM and validate the effectiveness of PM/DM treatment. This evidence concerns the gene IRF9 and dermatomyositis.